DSIP 1mg/mL (5mL)

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide that has been studied for its role in sleep regulation, deep (slow-wave) sleep promotion, and stress modulation. It was originally isolated based on its ability to induce delta EEG activity and reduce motor activity in animal models, suggesting involvement in deep restorative sleep processes. Research has explored DSIP’s effects on sleep architecture, with some controlled studies showing improvements in sleep efficiency and reduced sleep latency compared with placebo, though effects can be modest and variable. Other clinical investigations have suggested that DSIP may normalize disturbed sleep patterns, improve daytime alertness, and support stress tolerance, though results are mixed and not universally replicated. Beyond sleep, some research indicates DSIP might influence neuroendocrine regulation, including interactions with stress hormone axes and potential roles in pain modulation or neuroprotection, but these findings are preliminary and largely from early studies or animal models. A 1 mg/mL (5 mL) vial is a common compounded peptide formulation used in research or clinical peptide therapy settings, typically administered subcutaneously under medical supervision. DSIP is not FDA-approved as a therapeutic drug, and its clinical use is considered investigational with limited high-quality human data.